Best supportive care in combination with polychemotherapy versus best supportive care alone as second-line therapy in stage IV metastatic melanoma (DeCOG MM-PAL 8)

被引：0
|
作者：
Ulrich, J.
Trefzer, U.
Tilgen, W.
Schadendorf, D.
Kaatz, M.
Mohr, P.
Garbe, C.
Hauschild, A.
机构：
[1] Med Ctr, Quedlinburg, Germany
[2] Univ Berlin Charite, Berlin, Germany
[3] Univ Saarland, Homburg, Germany
[4] German Canc Res Ctr, Mannheim, Germany
[5] Univ Med Ctr, Jena, Germany
[6] Med Ctr, Buxtehude, Germany
[7] Univ Med Ctr, Tubingen, Germany
[8] Univ Med Ctr, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8567
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
    Gardini, Andrea Casadei
    Foca, Flavia
    Scartozzi, Mario
    Silvestris, Nicola
    Tamburini, Emiliano
    Faloppi, Luca
    Brunetti, Oronzo
    Rudnas, Britt
    Pisconti, Salvatore
    Valgiusti, Martina
    Marisi, Giorgia
    Foschi, Francesco Giuseppe
    Ercolani, Giorgio
    Tassinari, Davide
    Cascinu, Stefano
    Frassineti, Giovanni Luca
    SCIENTIFIC REPORTS, 2017, 7
  • [2] Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
    Andrea Casadei Gardini
    Flavia Foca
    Mario Scartozzi
    Nicola Silvestris
    Emiliano Tamburini
    Luca Faloppi
    Oronzo Brunetti
    Britt Rudnas
    Salvatore Pisconti
    Martina Valgiusti
    Giorgia Marisi
    Francesco Giuseppe Foschi
    Giorgio Ercolani
    Davide Tassinari
    Stefano Cascinu
    Giovanni Luca Frassineti
    Scientific Reports, 7
  • [3] Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
    Xie, Qian
    Zheng, Hanrui
    Chen, Ye
    Peng, Xingchen
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [4] Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
    Qin, Shukui
    Chen, Zhendong
    Fang, Weijia
    Ren, Zhenggang
    Xu, Ruocai
    Ryoo, Baek-Yeol
    Meng, Zhiqiang
    Bai, Yuxian
    Chen, Xiaoming
    Liu, Xiufeng
    Xiao, Juxiang
    Ho, Gwo Fuang
    Mao, Yimin
    Ye, Xing
    Ying, Jieer
    Li, Jianfeng
    Zhong, Wen Yan
    Zhou, Yu
    Siegel, Abby B.
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003).
    Oettle, H
    Pelzer, U
    Stieler, J
    Hilbig, A
    Roll, L
    Schwaner, I
    Adler, M
    Detken, S
    Dörken, B
    Riess, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 315S - 315S
  • [6] A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
    Su, Po-Jung
    Xiao, Ying
    Lin, Amy Y.
    Goh, Connie
    Wu, Ethan
    Liu, Kevin
    Chou, Patrick
    Kuo, Kaitlin
    Palencia, Roberto
    Chang, Jane
    Kearney, Mairead
    Kapetanakis, Venediktos
    Benedict, Agnes
    CANCER REPORTS, 2023,
  • [7] A RETROSPECTIVE ANALYSIS OF SECOND-LINE CHEMOTHERAPY VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH ADVANCED GASTRIC CANCER (AGC)
    Park, S. H.
    Kim, Y. S.
    Hong, J.
    Sym, S. J.
    Cho, E. K.
    Shin, D. B.
    ANNALS OF ONCOLOGY, 2008, 19 : 176 - 176
  • [8] Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma
    Han, Jiaqi
    Lan, Xiaomeng
    Tian, Kun
    Shen, Xi
    He, Jinlan
    Chen, Nianyong
    FRONTIERS IN PUBLIC HEALTH, 2023, 10
  • [9] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Fernandes, R. A.
    Schiola, A.
    VALUE IN HEALTH, 2009, 12 (03) : A42 - A42
  • [10] Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma (vol 10, 837854, 2022)
    Xie, Qian
    Zheng, Hanrui
    Chen, Ye
    Peng, Xingchen
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
12345